NPM1突变急性髓系白血病中染色体异常与预后:九项国际队列个体患者数据汇总分析
该汇总分析纳入九项国际队列中2,426例强化治疗的NPM1突变/FLT3-ITD阴性或低等位基因比AML患者,评估核型与预后的关联。结果显示不良风险染色体异常与较低完全缓解率、较差5年总生存和无事件生存及较高累积复发率显著相关,且多变量分析后仍显著。结论:细胞遗传学风险在NPM1突变/FLT3-ITD阴性或低等位基因比AML中优先于分子风险。
要点
- NPM1突变/FLT3-ITD阴性或低等位基因比AML中,不良核型者预后显著差于正常或中等核型者。
- 不良风险染色体异常患者中,NPM1突变状态对预后无显著影响。
- 细胞遗传学风险应优先于分子风险用于该类患者的分类和治疗决策。
核心结论
- 在NPM1突变/FLT3-ITD阴性或低等位基因比AML中,核型异常与预后显著相关,不良风险细胞遗传学患者预后与NPM1野生型相同。
研究设计与样本
- 汇总分析九项国际研究组或治疗中心注册数据库中的2,426例强化治疗的NPM1突变/FLT3-ITD阴性或低等位基因比AML患者。
主要发现
- 2,426例中2,000例(82.4%)核型正常,426例(17.6%)异常,包括329例(13.6%)中等风险和83例(3.4%)不良风险染色体异常。
- 正常、中等异常和不良核型患者的完全缓解率分别为87.7%、86.0%和66.3%(P < .001)。
- 正常、中等异常和不良核型患者的5年总生存率分别为52.4%、44.8%和19.5%(P < .001)。
- 正常、中等异常和不良核型患者的5年无事件生存率分别为40.6%、36.0%和18.1%(P < .001)。
- 正常、中等异常和不良核型患者的5年累积复发率分别为43.6%、44.2%和51.9%(P = .0012)。
关键数值与推荐
- 不良风险染色体异常患者中,NPM1突变状态对预后无显著影响。
临床怎么用
- 对NPM1突变/FLT3-ITD阴性或低等位基因比AML患者,应依据细胞遗传学风险进行分层,不良风险者按高危分类和治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nucleophosmin 1 (NPM1) mutations are associated with a favorable prognosis in acute myeloid leukemia (AML) when an internal tandem duplication (ITD) in the fms-related tyrosine kinase 3 gene (FLT3) is absent (FLT3-ITDneg) or present with a low allelic ratio (FLT3-ITDlow). The 2017 European LeukemiaNet guidelines assume this is true regardless of accompanying cytogenetic abnormalities. We investigated the validity of this assumption. METHODS: We analyzed associations between karyotype and outcome in intensively treated patients with NPM1mut/FLT3-ITDneg/low AML who were prospectively enrolled in registry databases from nine international study groups or treatment centers. RESULTS: Among 2,426 patients with NPM1mut/FLT3-ITDneg/low AML, 2,000 (82.4%) had a normal and 426 (17.6%) had an abnormal karyotype, including 329 patients (13.6%) with intermediate and 83 patients (3.4%) with adverse-risk chromosomal abnormalities. In patients with NPM1mut/FLT3-ITDneg/low AML, adverse cytogenetics were associated with lower complete remission rates (87.7%, 86.0%, and 66.3% for normal, aberrant intermediate, and adverse karyotype, respectively; P < .001), inferior 5-year overall (52.4%, 44.8%, 19.5%, respectively; P < .001) and event-free survival (40.6%, 36.0%, 18.1%, respectively; P < .001), and a higher 5-year cumulative incidence of relapse (43.6%, 44.2%, 51.9%, respectively; P = .0012). These associations remained in multivariable mixed-effects regression analyses adjusted for known clinicopathologic risk factors (P < .001 for all end points). In patients with adverse-risk chromosomal aberrations, we found no significant influence of the NPM1 mutational status on outcome. CONCLUSION: Karyotype abnormalities are significantly associated with outcome in NPM1mut/FLT3-ITDneg/low AML. When adverse-risk cytogenetics are present, patients with NPM1mut share the same unfavorable prognosis as patients with NPM1 wild type and should be classified and treated accordingly. Thus, cytogenetic risk predominates over molecular risk in NPM1mut/FLT3-ITDneg/low AML.
引用
- Angenendt L, Röllig C, Montesinos P, et al. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019. PMID: 31430225. doi:10.1200/JCO.19.00416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。